Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction-Reference-Cited by-同舟云学术

Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction

Published:2023-04-13 Issue: Volume: Page:
ISSN:0920-3206
Container-title:Cardiovascular Drugs and Therapy
language:en
Short-container-title:Cardiovasc Drugs Ther

Author:

Sakhuja Swati^ORCID,Bittner Vera A.,Brown Todd M.,Farkouh Michael E.,Levitan Emily B.,Safford Monika M.,Woodward Mark,Chen Ligong,Sun Ruoyan,Dhalwani Nafeesa,Jones Jenna,Kalich Bethany,Exter Jason,Muntner Paul,Rosenson Robert S.,Colantonio Lisandro D.

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,Pharmacology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10557-023-07452-1.pdf

Reference36 articles.

1. Li S, Peng Y, Wang X, et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391–9.

2. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163–70.

3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 Guideline on the Management of Blood Cholesterol. J Amer Coll Cardiol. 2019;73(24):e285–350.